⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for idh2

Every month we try and update this database with for idh2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 MutationNCT02632708
Newly Diagnosed...
Untreated AML
AML Arising Fro...
AML Arising Fro...
AML Arising Aft...
AG-120
AG-221
cytarabine
daunorubicin
idarubicin
mitoxantrone
etoposide
18 Years - Servier
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted TherapyNCT03499912
Acute Myeloid L...
20 Years - 100 YearsNational Taiwan University Hospital
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 MutationNCT02492737
Acute Myeloid L...
Myelodysplastic...
Hematologic Mal...
AG881
18 Years - Agios Pharmaceuticals, Inc.
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 MutationNCT02632708
Newly Diagnosed...
Untreated AML
AML Arising Fro...
AML Arising Fro...
AML Arising Aft...
AG-120
AG-221
cytarabine
daunorubicin
idarubicin
mitoxantrone
etoposide
18 Years - Servier
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 MutationNCT02492737
Acute Myeloid L...
Myelodysplastic...
Hematologic Mal...
AG881
18 Years - Agios Pharmaceuticals, Inc.
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 MutationNCT02481154
Glioma
AG881
18 Years - Servier
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: